Serum level of TNF-α, IL-1 and IL-6 and serum biomarkers after nutritional change in patients’ ventilator-associated pneumonia
serum biomarkers in ventilator-associated pneumonia
Abstract
Objective: The research targets to explore the clinical research of high-protein nutritional support combined with probiotics (Bifid Triple Live Bacteria Capsules) to improve critically ill patients’ nutritional conditions and prevent ventilator-associated pneumonia and clinical value of TNF-α, IL-1 and IL-6 and serum biomarkers. Methods: 86 critically ill patients requiring continuous ventilator support in the ICU department of the central hospital from March 2023 to December 2024 are recruited as study objects. Patients are randomly broken into the research group (n=46) or the control group (n=40). Both groups are given enteral nutrition emulsion TPF (Rexen), and whey protein powder is given nutritional support according to the total protein intake standard of 1.5~2.0g/kcal/d. On the basis of the control group, the research group receive individualized high-protein nutritional support, supplemented by probiotics (bifidobacteria triple live capsule) intervention. The study period is 3 weeks. The clinical data of the two groups are statistically compared. The patients' body mass index (BMI) and body weight are calculated and compared. The content of serum protein is measured by spectrophotometer. The prevalence of ventilator-associated pneumonia is analyzed by sputum gram staining. The clinical symptoms of patients with ventilator-associated pneumonia during ICU are monitored. Serum levels of inflammatory cytokines TNF-α, IL-1 and IL-6 are detected by ELISA. Results: There was no difference in general data between the two groups (P>0.05). The body weight and BMI of the patients in the research group were higher than those in the control group (P<0.05). The content of serum albumin, serum prealbumin and the ratio of serum albumin/total protein in the research group were higher than those in the control group (P<0.05). The infection rate of ventilator-associated pneumonia in the control group was higher than that in the research group (P<0.05). The incidence of clinical symptoms of ventilator-associated pneumonia in the research group was lower than that in the control group (P<0.05). The levels of serum TNF-α, IL-1 and IL-6 in the research group were lower than those in the control group (P<0.05). Conclusion: High-protein nutritional support combined with probiotics can significantly raise the nutritional conditions of critically ill patients, and can effectively prevent the occurrence of ventilator-associated pneumonia. This intervention may play a role by promoting the nutritional level of patients and regulating the inflammatory response, and has potential clinical application value in the management of critically ill patients in ICU.
References
[2] Santacroce L, Inchingolo F, Topi S, et al. Potential beneficial role of probiotics on the outcome of COVID-19 patients: An evolving perspective[J]. Diabetes Metab Syndr, 2021, 15:295-301.
[3] Debnath N, Kumar A, Yadav AK. Probiotics as a biotherapeutics for the management and prevention of respiratory tract diseases[J]. Microbiol Immunol, 2022, 66:277-291.
[4] Inchingolo AD, Cazzolla AP, Di Cosola M, et al. The integumentary system and its microbiota between health and disease[J]. J Biol Regul Homeost Agents, 2021, 35:303-321.
[5] Millares L, Monso E. The Microbiome in COPD: Emerging Potential for Microbiome-Targeted Interventions[J]. Int J Chron Obstruct Pulmon Dis, 2022, 17:1835-1845.
[6] Rastogi S, Singh A, Nandi A, et al. Can the Therapeutic Spectrum of Probiotics be Extended: Exploring Potential of Gut Microbiome[J]. Recent Adv Antiinfect Drug Discov, 2023, 18:120-147.
[7] Johnstone J, Meade M, Lauzier F, et al. Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients: A Randomized Clinical Trial[J]. Jama, 2021, 326:1024-1033.
[8] Hasslöf P, Granqvist L, Stecksén-Blicks C, et al. Prevention of Recurrent Childhood Caries with Probiotic Supplements: A Randomized Controlled Trial with a 12-Month Follow-Up[J]. Probiotics Antimicrob Proteins, 2022, 14:384-390.
[9] Bayoumy AB, Mulder CJJ, Mol JJ, et al. Gut fermentation syndrome: A systematic review of case reports[J]. United European Gastroenterol J, 2021, 9:332-342.
[10] Ji T, Zhu X, Shang F, et al. Preventive Effect of Probiotics on Ventilator-Associated Pneumonia: A Meta-analysis of 2428 Patients[J]. Ann Pharmacother, 2021, 55:949-962.
[11] Linares-García L, Cárdenas-Barragán ME, Hernández-Ceballos W, et al. Bacterial and Fungal Gut Dysbiosis and Clostridium difficile in COVID-19: A Review[J]. J Clin Gastroenterol, 2022, 56:285-298.
[12] Lau VI, Xie F, Fowler RA, et al. Health economic evaluation alongside the Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial (E-PROSPECT): a cost-effectiveness analysis[J]. Can J Anaesth, 2022, 69:1515-1526.
[13] Shenoy S. Gut microbiome, Vitamin D, ACE2 interactions are critical factors in immune-senescence and inflammaging: key for vaccine response and severity of COVID-19 infection[J]. Inflamm Res, 2022, 71:13-26.
[14] Wang B, Xie J, Teng Y. A meta-analysis of the effects of probiotics on various parameters in critically ill ventilated individuals[J]. Adv Clin Exp Med, 2023, 32:633-642.
[15] Chen Y, Qi A, Teng D, et al. Probiotics and synbiotics for preventing postoperative infectious complications in colorectal cancer patients: a systematic review and meta-analysis[J]. Tech Coloproctol, 2022, 26:425-436.
[16] Sencio V, Machado MG, Trottein F. The lung-gut axis during viral respiratory infections: the impact of gut dysbiosis on secondary disease outcomes[J]. Mucosal Immunol, 2021, 14:296-304.
[17] Heidari Z, Tajbakhsh A, Gheibihayat SM, et al. Probiotics/Prebiotics in Viral Respiratory Infections: Implication for Emerging Pathogens[J]. Recent Pat Biotechnol, 2021, 15:112-136.
[18] Mirzaei R, Attar A, Papizadeh S, et al. The emerging role of probiotics as a mitigation strategy against coronavirus disease, 2019 (COVID-19)[J]. Arch Virol, 2021, 166:1819-1840.
[19] Sharif S, Greer A, Skorupski C, et al. Probiotics in Critical Illness: A Systematic Review and Meta-Analysis of Randomized Controlled Trials[J]. Crit Care Med, 2022, 50:1175-1186.
[20] Vázquez-Frias R, Consuelo-Sánchez A, Acosta-Rodríguez-Bueno CP, et al. Efficacy and Safety of the Adjuvant Use of Probiotic Bacillus clausii Strains in Pediatric Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study[J]. Paediatr Drugs, 2023, 25:115-126.
[21] Rozga M, Cheng FW, Handu D. Effects of Probiotics in Conditions or Infections Similar to COVID-19 on Health Outcomes: An Evidence Analysis Center Scoping Review[J]. J Acad Nutr Diet, 2021, 121:1841-1854.
[22] Wang Y, Li N, Li Q, et al. Xuanbai Chengqi Decoction Ameliorates Pulmonary Inflammation via Reshaping Gut Microbiota and Rectifying Th17/Treg Imbalance in a Murine Model of Chronic Obstructive Pulmonary Disease[J]. Int J Chron Obstruct Pulmon Dis, 2021, 16:3317-3335.
[23] Şenöztop E, Dokuzlu T, Güngörmüşler M. A comprehensive review on the development of probiotic supplemented confectioneries[J]. Z Naturforsch C J Biosci, 2022, 77:71-84.
[24] Manna S, Chowdhury T, Chakraborty R, et al. Probiotics-Derived Peptides and Their Immunomodulatory Molecules Can Play a Preventive Role Against Viral Diseases Including COVID-19[J]. Probiotics Antimicrob Proteins, 2021, 13:611-623.
[25] El-Sayed EM, Ibrahim KS. Ameliorating effects of probiotics on alterations in iron homeostasis and inflammation in COVID-19[J]. Mol Biol Rep, 2022, 49:5153-5163
Copyright (c) 2025 Peng Lu
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.